Manitoba Institute of Cell Biology, Cancer Care Manitoba, Department of Physiology, University of Manitoba, Winnipeg, Manitoba R3E 0V9, Canada.
Cancers (Basel). 2013 Aug 22;5(3):1086-102. doi: 10.3390/cancers5031086.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the t(9;22) translocation. As in most cancers, short telomeres are one of the features of CML cells, and telomere shortening accentuates as the disease progresses from the chronic phase to the blastic phase. Although most individual telomeres are short, some of them are lengthened, and long individual telomeres occur non-randomly and might be associated with clonal selection. Telomerase is the main mechanism used to maintain telomere lengths, and its activity increases when CML evolves toward advanced stages. ALT might be another mechanism employed by CML cells to sustain the homeostasis of their telomere lengths and this mechanism seems predominant at the early stage of leukemogenesis. Also, telomerase and ALT might jointly act to maintain telomere lengths at the chronic phase, and as CML progresses, telomerase becomes the major mechanism. Finally, CML cells display an altered nuclear organization of their telomeres which is characterized by the presence of high number of telomeric aggregates, a feature of genomic instability, and differential positioning of telomeres. CML represents a good model to study mechanisms responsible for dynamic changes of individual telomere lengths and the remodeling of telomeric nuclear organization throughout cancer progression.
慢性髓性白血病(CML)是一种骨髓增生性肿瘤,其特征是 t(9;22)易位。与大多数癌症一样,CML 细胞的一个特征是端粒较短,随着疾病从慢性期发展到急变期,端粒缩短加剧。尽管大多数单个端粒较短,但其中一些会延长,并且长的单个端粒会非随机发生,可能与克隆选择有关。端粒酶是维持端粒长度的主要机制,当 CML 向晚期发展时,其活性会增加。ALT 可能是 CML 细胞用来维持其端粒长度的另一种机制,这种机制在白血病发生的早期似乎占主导地位。此外,端粒酶和 ALT 可能共同作用来维持慢性期的端粒长度,随着 CML 的进展,端粒酶成为主要机制。最后,CML 细胞表现出其端粒的核组织改变,其特征是存在大量端粒聚集物,这是基因组不稳定性的一个特征,以及端粒的不同定位。CML 是研究负责个体端粒长度动态变化和端粒核组织在整个癌症进展过程中重塑的机制的良好模型。